Cargando…

EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells

Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hester, Anna, Salzmann, Barbara, Rahmeh, Martina, Kolben, Thomas, Czogalla, Bastian, Ditsch, Nina, Mahner, Sven, Jeschke, Udo, Kolben, Theresa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680222/
https://www.ncbi.nlm.nih.gov/pubmed/31534346
http://dx.doi.org/10.2147/OTT.S204919
_version_ 1783441456609886208
author Hester, Anna
Salzmann, Barbara
Rahmeh, Martina
Kolben, Thomas
Czogalla, Bastian
Ditsch, Nina
Mahner, Sven
Jeschke, Udo
Kolben, Theresa Maria
author_facet Hester, Anna
Salzmann, Barbara
Rahmeh, Martina
Kolben, Thomas
Czogalla, Bastian
Ditsch, Nina
Mahner, Sven
Jeschke, Udo
Kolben, Theresa Maria
author_sort Hester, Anna
collection PubMed
description Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeting EP3 in breast cancer cell lines. Material and methods: EP3 and EP1 expressions were determined in five breast cancer cell lines on the mRNA- and the protein-level. The selected cell lines were subsequently stimulated for 24–72 hrs with 10–1,000 nM of PGE2, the EP1/EP3 agonist sulprostone and the EP3 antagonist L798,106. Cell proliferation was determined via BrdU-assay, migration via scratch assay, EP3, Gi-protein and p-ERK1/2 expressions via Western blot and cAMP concentrations via ELISA. The Mann–Whitney-U-test was used to test for statistical significance. Results: The cell lines T-47D (EP3 expression 77.7%) and SK-BR-3 (EP3 expression 48.7%) were chosen. EP3 antagonism reduced its expression on SK-BR-3 significantly, while no effect was observed on T-47D. The proliferation and migration of SK-BR-3 cells were significantly reduced due to treatment with the EP1/3 agonist, the EP3 antagonist or a combination of both. Neither agonism nor antagonism influenced cell proliferation or migration in T-47D. In SK-BR-3, EP3 antagonism showed a significant decrease in Gi-protein levels, an increase in cAMP levels, and no significant change in p-ERK1/2 expression. Conclusion: Antagonism of the EP3 receptor results in a reduced proliferation and migration of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway. The results suggest that EP3 plays a role in tumorigenesis. This is in accordance with the cell culture data of other gynecological tumors, but it is conflicting in so far, as positive EP3 expression is clinically a positive prognostic marker in breast cancer. Therefore, other factors may be important in explaining this contradiction.
format Online
Article
Text
id pubmed-6680222
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66802222019-09-18 EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells Hester, Anna Salzmann, Barbara Rahmeh, Martina Kolben, Thomas Czogalla, Bastian Ditsch, Nina Mahner, Sven Jeschke, Udo Kolben, Theresa Maria Onco Targets Ther Original Research Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeting EP3 in breast cancer cell lines. Material and methods: EP3 and EP1 expressions were determined in five breast cancer cell lines on the mRNA- and the protein-level. The selected cell lines were subsequently stimulated for 24–72 hrs with 10–1,000 nM of PGE2, the EP1/EP3 agonist sulprostone and the EP3 antagonist L798,106. Cell proliferation was determined via BrdU-assay, migration via scratch assay, EP3, Gi-protein and p-ERK1/2 expressions via Western blot and cAMP concentrations via ELISA. The Mann–Whitney-U-test was used to test for statistical significance. Results: The cell lines T-47D (EP3 expression 77.7%) and SK-BR-3 (EP3 expression 48.7%) were chosen. EP3 antagonism reduced its expression on SK-BR-3 significantly, while no effect was observed on T-47D. The proliferation and migration of SK-BR-3 cells were significantly reduced due to treatment with the EP1/3 agonist, the EP3 antagonist or a combination of both. Neither agonism nor antagonism influenced cell proliferation or migration in T-47D. In SK-BR-3, EP3 antagonism showed a significant decrease in Gi-protein levels, an increase in cAMP levels, and no significant change in p-ERK1/2 expression. Conclusion: Antagonism of the EP3 receptor results in a reduced proliferation and migration of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway. The results suggest that EP3 plays a role in tumorigenesis. This is in accordance with the cell culture data of other gynecological tumors, but it is conflicting in so far, as positive EP3 expression is clinically a positive prognostic marker in breast cancer. Therefore, other factors may be important in explaining this contradiction. Dove 2019-07-29 /pmc/articles/PMC6680222/ /pubmed/31534346 http://dx.doi.org/10.2147/OTT.S204919 Text en © 2019 Hester et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hester, Anna
Salzmann, Barbara
Rahmeh, Martina
Kolben, Thomas
Czogalla, Bastian
Ditsch, Nina
Mahner, Sven
Jeschke, Udo
Kolben, Theresa Maria
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title_full EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title_fullStr EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title_full_unstemmed EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title_short EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
title_sort ep3 receptor antagonist l798,106 reduces proliferation and migration of sk-br-3 breast cancer cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680222/
https://www.ncbi.nlm.nih.gov/pubmed/31534346
http://dx.doi.org/10.2147/OTT.S204919
work_keys_str_mv AT hesteranna ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT salzmannbarbara ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT rahmehmartina ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT kolbenthomas ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT czogallabastian ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT ditschnina ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT mahnersven ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT jeschkeudo ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells
AT kolbentheresamaria ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells